TAT-Cx43266-283 inhibits the oncogenic activity of Src and exerts important anti-tumoral effects in several preclinical models of glioblastoma in vitro, ex vivo, and in vivo, including freshly removed surgical specimens from patients [54, 135]. Here, SRC is linked to glioblastoma.